Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome

Abstract

Tofacitinib suppressed the induction of <i>NOD2</i> by IFNγ, thereby inhibiting the production of pro-inflammatory cytokines. Thus, tofacitinib showed anti-inflammatory effects through suppression of <i>NOD2</i> expression. The JAK inhibitor tofacitinib is a potential therapeutic agent for Blau syndrome because it suppresses the autoinflammation seen in Blau syndrome by inhibiting the expression of <i>NOD2</i>.